Monte Rosa Therapeutics (GLUE) Profit After Tax (2023 - 2025)
Historic Profit After Tax for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Q3 2025 value amounting to -$27.1 million.
- Monte Rosa Therapeutics' Profit After Tax fell 1350.43% to -$27.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.9 million, marking a year-over-year increase of 11753.73%. This contributed to the annual value of -$72.7 million for FY2024, which is 4630.72% up from last year.
- As of Q3 2025, Monte Rosa Therapeutics' Profit After Tax stood at -$27.1 million, which was down 1350.43% from -$12.3 million recorded in Q2 2025.
- Over the past 5 years, Monte Rosa Therapeutics' Profit After Tax peaked at $46.9 million during Q1 2025, and registered a low of -$35.2 million during Q2 2023.
- In the last 3 years, Monte Rosa Therapeutics' Profit After Tax had a median value of -$30.3 million in 2024 and averaged -$18.2 million.
- Within the past 5 years, the most significant YoY rise in Monte Rosa Therapeutics' Profit After Tax was 24666.23% (2025), while the steepest drop was 1350.43% (2025).
- Quarter analysis of 3 years shows Monte Rosa Therapeutics' Profit After Tax stood at -$33.3 million in 2023, then soared by 140.35% to $13.4 million in 2024, then crashed by 301.54% to -$27.1 million in 2025.
- Its last three reported values are -$27.1 million in Q3 2025, -$12.3 million for Q2 2025, and $46.9 million during Q1 2025.